Published in Nat Rev Immunol on January 01, 2015
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet (2015) 1.21
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol (2015) 0.98
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res (2016) 0.96
Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92
Emerging therapeutic agents for lung cancer. J Hematol Oncol (2016) 0.88
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS One (2015) 0.86
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. Oncotarget (2016) 0.85
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol (2016) 0.84
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 0.83
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
The immune network in thyroid cancer. Oncoimmunology (2016) 0.80
PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology (2015) 0.80
Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med (2016) 0.80
DPP4 in anti-tumor immunity: going beyond the enzyme. Nat Immunol (2015) 0.79
Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther (2016) 0.79
PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathog (2015) 0.79
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer (2016) 0.79
Pembrolizumab (Keytruda). Hum Vaccin Immunother (2016) 0.78
Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol (2016) 0.78
Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget (2016) 0.78
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells. Int J Cancer (2016) 0.77
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Oncotarget (2016) 0.77
T cell metabolic reprogramming and plasticity. Mol Immunol (2015) 0.76
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. J Immunother Cancer (2015) 0.76
Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol (2016) 0.76
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res (2016) 0.75
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. Oncoimmunology (2016) 0.75
Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro. Can J Vet Res (2017) 0.75
Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators. Oncoimmunology (2015) 0.75
Lymphocyte activation gene 3 and coronary artery disease. JCI Insight (2016) 0.75
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (2016) 0.75
IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod). J Immunol (2016) 0.75
Mesenchymal stromal cells as regulators of anti-tumour immune response. Indian J Med Res (2015) 0.75
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun (2017) 0.75
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer (2017) 0.75
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget (2016) 0.75
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap (2015) 0.75
Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight (2017) 0.75
Functional impairment of infiltrating T cells in human colorectal cancer. Oncoimmunology (2016) 0.75
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity. Sci Rep (2016) 0.75
Expanding the antimalarial toolkit: Targeting host-parasite interactions. J Exp Med (2016) 0.75
PD-1 pathway-mediated regulation of islet-specific CD4(+) T cell subsets in autoimmune diabetes. Immunoendocrinology (Houst) (2016) 0.75
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer (2016) 0.75
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol (2016) 0.75
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel) (2016) 0.75
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). PLoS One (2017) 0.75
Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy. ACS Omega (2017) 0.75
Epigenetic Modification Mediates the Increase of LAG-3(+) T Cells in Chronic Osteomyelitis. Inflammation (2016) 0.75
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics (2017) 0.75
Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol (2017) 0.75